Biotechnology company developing a functional proteomics and AI platform for structure-free drug discovery
Biotechnology company developing a functional proteomics and AI platform for structure-free drug discovery. Its MARMOT technology profiles protein dynamics and compound–protein interactions in living human cells, while Ptarmigan-1 predicts small-molecule engagement across the human proteome, including disordered and previously undruggable targets such as transcription factors. The company focuses on discovering and optimizing therapeutics for oncology, autoimmune disease, and other areas.